about
Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvementCardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study.Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities StudyGenome-Wide Association Study of Staphylococcus aureus Carriage in a Community-Based Sample of Mexican-Americans in Starr County, Texas.Correlates of Segmental Pulse Wave Velocity in Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study.Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study.Chagas cardiomyopathy is associated with higher incidence of stroke: a meta-analysis of observational studies.Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease.Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod.Smoking Behaviors and Arterial Stiffness Measured by Pulse Wave Velocity in Older Adults: The Atherosclerosis Risk in Communities (ARIC) StudyTreating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus.Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study.Echocardiographic changes during treatment of acute decompensated heart failure: insights from the ESCAPE trial.Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease: A Clinical Conundrum.Functionally oriented analysis of cardiometabolic traits in a trans-ethnic sampleResponse to Letter Regarding Article, “Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study”A Multi-Trait Approach Identified Genetic Variants Including a Rare Mutation in RGS3 with Impact on Abnormalities of Cardiac Structure/FunctionAntihypertensive drug use and blood pressure control among stroke survivors in the United States: NHANES 2003-2014Improving Outcomes in Patients With Diabetes MellitusPlasma Galectin-3 and Sonographic Measures of Carotid Atherosclerosis in the Atherosclerosis Risk in Communities StudyHabitual physical activity and central artery stiffening in older adults: the Atherosclerosis Risk in Communities studyGalectin-3 and Venous Thromboembolism Incidence: the Atherosclerosis Risk in Communities (ARIC) StudyAssociation of Serum Folate Levels With Cardiovascular Mortality Among Adults With Rheumatoid ArthritisStrategies of Unloading the Failing Heart from Metabolic StressEffects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular DiseaseTaking the Air Out of Oxygen Supplementation in Individuals With Diabetes and Acute Coronary SyndromesSleep apnea and galectin-3: possible sex-specific relationshipMetabolomic profiles associated with subtypes of prediabetes among Mexican Americans in Starr County, Texas, USAEditor's Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarctionUnderstanding by General Providers of the Echocardiogram ReportType 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline updateType 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of AmericaCorrigendum to "Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America" Journal of Cardiac Failure Vol. 25 No. 8, pp. 584-619
P50
Q27003819-A164D319-7C80-4F0D-8BD6-075DF1010445Q35630009-E398990E-409B-4636-98F8-95A434032FB3Q35784557-5E1F55B8-D0F7-4915-8E37-A20962DC68F8Q35841552-B92C770E-CD4D-4980-8067-B3C312326CFDQ36408982-5CE511AC-D9C8-4D6E-AEA4-2333F634DE60Q36820589-FF03A541-2BAE-40DC-9879-EE648D2E4FFBQ38250414-ED642D33-6693-4334-94CC-9B5E35B9437EQ40060474-D4DA7B01-FEE0-4C21-9BF2-FE81F6346B6AQ40948527-DD7EA537-6899-4984-B041-5983ED483182Q41069553-89C347AA-F262-4D36-8E38-1D547994BA12Q42681154-2CFB7FA5-44FA-4D9A-8D44-CEB1B3B10A04Q47672213-A0EDCB31-5E11-48F8-BEC2-2CE95260E899Q47759940-90AD86CC-49BB-4C04-986B-836EFD59B407Q48600478-40CBC65E-7371-4C8F-8B4D-1CCF6D2F1192Q53752136-C3DB5A1F-2F8F-4A85-8F92-C69C605521B5Q60698048-E9B2922B-81F1-4E2B-B8AE-F5A65B026DF3Q62141319-FAF3BBDE-FC7C-496F-8D01-1D28D825C348Q64061821-76CAD573-6BCE-4BC6-AAD7-37BDD32C47EFQ64108833-BE927333-1F19-4086-9B0D-BC1A60F89040Q64241845-D704D228-83F1-4E33-BC86-217A6C990568Q89027396-9AB8C62C-C2B8-41F9-9B6F-DB4ACD27B7B3Q89233629-11772B9E-EF6A-4B65-AC51-80BB00B876F9Q89313843-E0508A6D-F824-4B34-9C99-9C17BD034EC2Q89891732-67E2EA34-860F-4C8C-9A4E-3C30B6144A35Q90104647-6516D4A7-721A-4D33-BE03-BAA11DF26B0CQ90667643-66261A81-335A-4BB6-B7C8-470B1C0EA4E3Q90856413-66F403CF-91E3-4F34-AA8F-BCB774A82FE5Q91352594-C567F741-443F-4CC9-BE2E-FB22B062D9CAQ91699129-85DA9F65-845E-41C3-A374-476D902CD957Q91799977-28DE7268-8BEA-4B46-B52B-B8FD3057186FQ92142560-3F9F6A36-C346-44FB-87D7-F36B5804E3BBQ92544767-5F17A7AC-8AA5-482E-A7DC-A6973E701416Q92593588-EEAA700A-9858-429E-9675-B8C516D50F76Q92830595-CC4DA2CC-B2FC-4616-9136-7706DCAAC18D
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
David Aguilar
@en
David Aguilar
@nl
type
label
David Aguilar
@en
David Aguilar
@nl
prefLabel
David Aguilar
@en
David Aguilar
@nl
P31
P496
0000-0002-0916-2722